AXT914 | 717104-43-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: AXT914
• 英文别名: 1-[(4-bromophenyl)methyl]-4-(4-propan-2-ylphenyl)-6-prop-2-ynoxyquinazolin-2-one
• CAS: 717104-43-3
• 化学式: C₂₇H₂₃BrN₂O₂
• 分子量: 487.396
• InChiKey: KIZITKARUSPCHY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.3
• 重原子数：
  32
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  41.9
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• Aryl-quinazoline/aryl-2amino-phenyl methanone derivatives
  申请人：Altmann Eva

  公开号：US20100063075A1

  公开（公告）日：2010-03-11

  A compound of formula (1): wherein R1, R2, R3 and Y are as defined herein, or a pharmaceutically-acceptable and -cleavable ester, or acid addition salt thereof, useful for promoting the release of parathyroid hormone, e.g. for preventing or treating bone conditions which are associated with increased calcium depletion or resorption or in which stimulation of bone formation and calcium fixation in the bone is desirable.

  式（1）的化合物：其中R1、R2、R3和Y的定义如本文所述，或其药学上可接受和可水解酯或酸加合物盐，有助于促进甲状旁腺激素的释放，例如用于预防或治疗与钙丢失或吸收增加有关的骨病或骨形成和钙固定在骨中的刺激是有益的。
• Derivatives of aryl-quinazoline/aryl-2-amino-phenyl methanone which promote the release of parathyroid hormone
  申请人：Novartis Pharma AG

  公开号：EP1844780A2

  公开（公告）日：2007-10-17

  A compound of formula I wherein R1, R2, R3 and Y are as defined herein, or a pharmaceutically-acceptable and -cleavable ester, or acid addition salt thereof, useful for promoting the release of parathyroid hormone, e.g. for preventing or treating bone conditions which are associated with increased calcium depletion or resorption or in which stimulation of bone formation and calcium fixation in the bone is desirable.

  式 I 的化合物 其中 R1、R2、R3 和 Y 如本文所定义、 或其药学上可接受和可清除的酯或酸加成盐、 可用于促进甲状旁腺激素的释放，例如用于预防或治疗与钙消耗或吸收增加有关的骨病，或用于刺激骨形成和钙在骨中的固定。
• PHARMACEUTICAL COMPOSITIONS COMPRISING A CALCILYTIC AGENT
  申请人：Novartis AG

  公开号：EP2124893A1

  公开（公告）日：2009-12-02
• PHARMACEUTICAL COMPOSITIONS
  申请人：Buhl Thomas

  公开号：US20100022565A1

  公开（公告）日：2010-01-28

  Provided is a pharmaceutical composition comprising a calcilytic agent which, when administered orally to a subject induces a rapid and short-lasting absorption of the calcilytic agent and/or a rapid and short-lasting release of the parathyroid hormone.
• PHARMACEUTICAL COMPOSITION FOR IMPROVING OR TREATING POST-SURGICAL HYPOPARATHYROIDISM AND TREATMENT METHOD USING THE SAME
  申请人：DONGGUK UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION

  公开号：US20220288076A1

  公开（公告）日：2022-09-15

  The present invention relates to a pharmaceutical composition for improving or treating hypoparathyroidism caused by damage to parathyroid tissue and vascular tissue around the parathyroid gland due to surgery around the neck, and a method for treating post-surgical hypoparathyroidism using the same, and the composition can promote secretion of parathyroid hormone by containing a calcium-sensing receptor antagonist as an active ingredient to help the restoration of damaged parathyroid tissue through neovascularization and angiogenesis, and furthermore, can alleviate hypocalcemia, hyperphosphatemia, and hypercalciuria by increasing the concentration of blood parathyroid hormone to a normal range level. Administration of the composition can improve the quality of life of patients with hypoparathyroidism.